BridgeBio presents data from ATTRibute-CM open label extension through month 42

BridgeBio (BBIO) Pharma presented data from the ATTRibute-CM open label extension through Month 42, which demonstrated a statistically significant reduction in CVM in the overall transthyretin amyloid cardiomyopathy population. These data were presented in an oral presentation at the European Society of Cardiology Congress 2025, taking place in Madrid, Spain from August 29 – September 1. Details from the oral presentation, Acoramidis Reduces Cardiovascular Mortality: Results at Month 42 from the ATTRibute-CM Open-Label Extension Study, presented by Dr. Alexander, included: Acoramidis treatment administered for 42 months led to a 44% hazard reduction in CVM compared with the placebo to acoramidis treatment group; These findings demonstrate the long-term clinical benefits of acoramidis for reducing CVM in ATTR-CM, and the importance of early and sustained treatment. “These results from the ATTRibute-CM open-label extension study add to the growing body of evidence supporting acoramidis as a potentially transformative therapy for patients with ATTR-CM. At 42 months post-randomization, acoramidis achieved an impressive 44% reduction in the hazard of cardiovascular mortality. These findings highlight acoramidis’s meaningful impact on patient outcomes and address a critical unmet need for those living with ATTR-CM,” said Kevin Alexander, M.D. of Stanford University School of Medicine, USA.